Device Trial Radar · NCT06059963
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
Last checked: Nov 20, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12,000
Planned (sponsor's estimate)
Start
Jan 18, 2024
Primary completion
Oct 30, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Universal DiagnosticsNot on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 29, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 45 years, up to 84 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.
Conditions
- Colorectal Cancer
- Advanced Adenocarcinoma
Interventions
Signal-C™Device
Signal-C™ is a qualitative next generation sequencing-based in vitro diagnostic assay that uses targeted hybridization-based capture next-generation sequencing together with bioinformatics and machine learning algorithm for detection and combination of methylation and fragmentation associated DNA marker regions. Signal-C™ utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected via venipuncture in Streck Cell-Free DNA Blood Collection Tubes (BCTs).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary ObjectiveTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gastroenterology Consultants of SW Virginia
Raonoke, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.